CHOODAPPA S. MUNICHOODAPPA, M.D., F.R.C.P.(C); SEARLE B. REES, M.D.; ROBERT F. BRADLEY, M.D., F.A.C.P.; MARIOS C. BALODIMOS, M.D.; GUENTHER BODEN, M.D.
Bragg peak proton beam irradiation of the pituitary gland for proliferative diabetic retinopathy was carried out in 56 patients. Most of them had been considered unsuitable for surgical hypophysectomy because of significant cardiovascular or renal disease, or both. Fifty-five were followed for an average of 4 years. Twenty-six attained moderate to maximal reduction in pituitary function; in 24 patients this occurred after a mean lapse of 7.2 months. Improvement or stabilization in vision was noted in 28 of 55 patients overall (51%), and in 10 of 13 (77%) after maximal pituitary suppression. Forty-six percent showed improvement in angiopathy. A positive correlation was noted between the degree of pituitary suppression and improvement or stabilization in vision and angiopathy. Two patients developed oculomotor nerve palsy. Recovery was complete in one and partial in the other. Bragg peak proton beam irradiation of the pituitary gland for proliferative diabetic retinopathy carries little morbidity and no mortality. It is a useful and safe tool, particularly in patients with compromised cardiovascular and renal status.
MUNICHOODAPPA CS, REES SB, BRADLEY RF, BALODIMOS MC, BODEN G. Bragg Peak Proton Beam Irradiation of the Pituitary Gland for Proliferative Diabetic Retinopathy. Ann Intern Med. ;74:491–498. doi: 10.7326/0003-4819-74-4-491
Download citation file:
Published: Ann Intern Med. 1971;74(4):491-498.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism, Neurology.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use